Do you support this bill?

Assembly Bill A2810B

2017-2018 Legislative Session

Requires practitioners who administer naloxone or another overdose reversal agent to a patient to report the administration of the agent to the prescription monitoring program registry

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

Bill Amendments

co-Sponsors

multi-Sponsors

2017-A2810 - Details

See Senate Version of this Bill:
S4374
Current Committee:
Assembly Codes
Law Section:
Public Health Law
Laws Affected:
Amd §3343-a, Pub Health L
Versions Introduced in Other Legislative Sessions:
2015-2016: A10656
2019-2020: A3741, S4482
2021-2022: S6045
2023-2024: S3350

2017-A2810 - Summary

Requires practitioners who administer naloxone or another overdose reversal agent to a patient in the case of a suspected or confirmed overdose to report the administration of the agent to the prescription monitoring program registry.

2017-A2810 - Bill Text download pdf 

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   2810
 
                        2017-2018 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 23, 2017
                                ___________
 
 Introduced by M. of A. McDONALD -- read once and referred to the Commit-
   tee on Health
 
 AN  ACT  to  amend  the  public health law, in relation to directing the
   department of health to include  information  regarding  the  adminis-
   tration  of  overdose  reversal  agents on the prescription monitoring
   program registry

   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision 9 of section 3343-a of the public health law is
 renumbered  subdivision  10  and a new subdivision 9 is added to read as
 follows:
   9. (A) NO LATER THAN JANUARY FIRST, TWO THOUSAND NINETEEN, THE DEPART-
 MENT SHALL INCLUDE  ON  THE  PRESCRIPTION  MONITORING  PROGRAM  REGISTRY
 INFORMATION  FOR  EACH  PERSON  TO  WHOM  NALOXONE  OR  ANOTHER OVERDOSE
 REVERSAL AGENT HAS BEEN DISPENSED TO ASSIST PHYSICIANS AND  OTHER  PRES-
 CRIBERS IDENTIFY PATIENTS WHO HAVE OVERDOSED ON AN OPIOID OR ON HEROIN.
   (B)  ANY  PERSON, INCLUDING A FIRST RESPONDER OR MEDICAL PRACTITIONER,
 WHO ADMINISTERS NALOXONE OR ANOTHER OVERDOSE REVERSAL AGENT TO A PATIENT
 IN THE CASE OF A SUSPECTED OR CONFIRMED OVERDOSE SHALL REPORT THE ADMIN-
 ISTRATION OF THE AGENT TO THE PRESCRIPTION MONITORING  PROGRAM  REGISTRY
 WITHIN  SEVENTY-TWO  HOURS  OF ADMINISTRATION. SUCH REPORT SHALL CONTAIN
 THE FOLLOWING INFORMATION IF AVAILABLE: (I) THE  NAME  OF  THE  PATIENT;
 (II) THE ADDRESS OF THE PATIENT; (III) THE DATE OF BIRTH OF THE PATIENT;
 (IV)  THE TIME AND PLACE OF THE ADMINISTRATION OF THE AGENT; AND (V) THE
 IDENTITY OF THE PERSON WHO ADMINISTERED THE NALOXONE TO THE PATIENT.
   (C) ANY REPORT MADE PURSUANT TO THE TERMS OF THIS SUBDIVISION SHALL BE
 CONSIDERED TO BE MADE BY THE REPORTER IN THE COURSE OF HIS OR HER DUTIES
 AND SHALL BE DIRECTLY RELATED TO PATIENT CARE.
   § 2. This act shall take effect immediately.

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD07660-01-7

co-Sponsors

multi-Sponsors

2017-A2810A - Details

See Senate Version of this Bill:
S4374
Current Committee:
Assembly Codes
Law Section:
Public Health Law
Laws Affected:
Amd §3343-a, Pub Health L
Versions Introduced in Other Legislative Sessions:
2015-2016: A10656
2019-2020: A3741, S4482
2021-2022: S6045
2023-2024: S3350

2017-A2810A - Summary

Requires practitioners who administer naloxone or another overdose reversal agent to a patient in the case of a suspected or confirmed overdose to report the administration of the agent to the prescription monitoring program registry.

2017-A2810A - Bill Text download pdf 

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  2810--A
 
                        2017-2018 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 23, 2017
                                ___________
 
 Introduced  by M. of A. McDONALD, MOSLEY, GALEF, HARRIS, JOYNER, TITONE,
   MONTESANO, MORINELLO,  CAHILL,  GOTTFRIED,  RAIA,  WOERNER,  LAWRENCE,
   BLAKE, B. MILLER, STECK, OTIS -- Multi-Sponsored by -- M. of A. BLANK-
   ENBUSH, BRAUNSTEIN, GIGLIO, HOOPER, McDONOUGH, SIMON, THIELE, WALSH --
   read  once  and  referred to the Committee on Health -- recommitted to
   the Committee on Health in accordance with Assembly Rule 3, sec. 2  --
   committee  discharged,  bill amended, ordered reprinted as amended and
   recommitted to said committee
 
 AN ACT to amend the public health law,  in  relation  to  directing  the
   department  of  health  to  include information regarding the adminis-
   tration of overdose reversal agents  on  the  prescription  monitoring
   program registry
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision 9 of section 3343-a of the public health law is
 renumbered subdivision 10 and a new subdivision 9 is added  to  read  as
 follows:
   9. ADMINISTRATION OF OVERDOSE REVERSAL AGENTS. (A) NO LATER THAN JANU-
 ARY  FIRST,  TWO  THOUSAND  TWENTY,  THE DEPARTMENT SHALL INCLUDE ON THE
 PRESCRIPTION MONITORING PROGRAM REGISTRY INFORMATION FOR EACH PERSON  TO
 WHOM  NALOXONE  OR ANOTHER OVERDOSE REVERSAL AGENT HAS BEEN DISPENSED TO
 ASSIST PHYSICIANS AND OTHER PRESCRIBERS IDENTIFY PATIENTS WHO HAVE OVER-
 DOSED ON AN OPIOID OR ON HEROIN.
   (B) ANY PRACTITIONER WHO  ADMINISTERS  NALOXONE  OR  ANOTHER  OVERDOSE
 REVERSAL  AGENT  TO  A  PATIENT  IN THE CASE OF A SUSPECTED OR CONFIRMED
 OVERDOSE  SHALL  REPORT  THE  ADMINISTRATION  OF  THE   AGENT   TO   THE
 PRESCRIPTION  MONITORING  PROGRAM  REGISTRY  WITHIN SEVENTY-TWO HOURS OF
 ADMINISTRATION. SUCH REPORT SHALL CONTAIN THE FOLLOWING  INFORMATION  IF
 AVAILABLE: (I) THE NAME OF THE PATIENT; (II) THE ADDRESS OF THE PATIENT;
 (III)  THE  DATE OF BIRTH OF THE PATIENT; (IV) THE TIME AND PLACE OF THE
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD07660-04-8

co-Sponsors

multi-Sponsors

2017-A2810B (ACTIVE) - Details

See Senate Version of this Bill:
S4374
Current Committee:
Assembly Codes
Law Section:
Public Health Law
Laws Affected:
Amd §3343-a, Pub Health L
Versions Introduced in Other Legislative Sessions:
2015-2016: A10656
2019-2020: A3741, S4482
2021-2022: S6045
2023-2024: S3350

2017-A2810B (ACTIVE) - Summary

Requires practitioners who administer naloxone or another overdose reversal agent to a patient in the case of a suspected or confirmed overdose to report the administration of the agent to the prescription monitoring program registry.

2017-A2810B (ACTIVE) - Bill Text download pdf 

                            
 
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  2810--B
 
                        2017-2018 Regular Sessions
 
                           I N  A S S E M B L Y
 
                             January 23, 2017
                                ___________
 
 Introduced by M. of A. McDONALD, MOSLEY, GALEF, JOYNER, TITONE, MONTESA-
   NO,  MORINELLO,  CAHILL,  GOTTFRIED,  RAIA,  WOERNER, LAWRENCE, BLAKE,
   B. MILLER, STECK, OTIS, PELLEGRINO -- Multi-Sponsored by -- M.  of  A.
   BLANKENBUSH,  BRAUNSTEIN,  GIGLIO,  HOOPER,  McDONOUGH, SIMON, THIELE,
   WALSH -- read once and referred to the Committee on Health  --  recom-
   mitted  to the Committee on Health in accordance with Assembly Rule 3,
   sec. 2 -- committee discharged, bill  amended,  ordered  reprinted  as
   amended  and recommitted to said committee -- again reported from said
   committee with amendments, ordered reprinted as amended and  recommit-
   ted to said committee
 
 AN  ACT to amend the public health law, in relation to requiring practi-
   tioners who administer naloxone or another overdose reversal agent  to
   a  patient  in the case of a suspected or confirmed overdose to report
   the administration of the agent to the prescription monitoring program
   registry
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Subdivision 9 of section 3343-a of the public health law is
 renumbered  subdivision  10  and a new subdivision 9 is added to read as
 follows:
   9. ADMINISTRATION OF OVERDOSE REVERSAL AGENTS.  (A)  ANY  PRACTITIONER
 WHO ADMINISTERS NALOXONE OR ANOTHER OVERDOSE REVERSAL AGENT TO A PATIENT
 IN THE CASE OF A SUSPECTED OR CONFIRMED OVERDOSE SHALL REPORT THE ADMIN-
 ISTRATION  OF  THE AGENT TO THE PRESCRIPTION MONITORING PROGRAM REGISTRY
 WITHIN SEVENTY-TWO HOURS OF ADMINISTRATION. SUCH  REPORT  SHALL  CONTAIN
 THE  FOLLOWING  INFORMATION  IF  AVAILABLE: (I) THE NAME OF THE PATIENT;
 (II) THE ADDRESS OF THE PATIENT; (III) THE DATE OF BIRTH OF THE PATIENT;
 (IV) THE TIME AND PLACE OF THE ADMINISTRATION OF THE AGENT; AND (V)  THE
 IDENTITY OF THE PERSON WHO ADMINISTERED THE NALOXONE TO THE PATIENT.

  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD07660-06-8

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.